Cardiovascular Health

Given the increasing value of patient satisfaction in determining the quality of care in the hospital reimbursement model, research is flourishing with a focus on identifying the factors that could positively influence patient satisfaction outcomes.

Less than 20% of physicians were open to starting a patient with nonvalvular atrial fibrillation on an anticoagulant after conducting a clinical review of the patient’s care.

The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m in the sotatercept group and 1 m in the placebo group among patients with pulmonary arterial hypertension.

Lowering blood pressure could be dangerous for people with normal blood pressure.

Poor sleep efficiency may contribute to vascular dysfunction with increasing exposure to adverse childhood experiences.

Neurovascular mechanisms cause the decrease in BP levels, results from a study of 23 participants in Brazil show.

The findings could inform revisions to safety guidelines and policies that help protect people with cardiovascular issues during heat waves.

A new scientific statement from the American Heart Association notes that the process falls short for those who are not white.

Limiting added or free sugar is recommended to reduce the adverse effects, especially in cardiometabolic disease.

It is important for pharmacists to educate patients, especially those with cardiovascular risks, about the differences between fish oil supplements and prescription n3-FAs products.

Many long-term therapies rely solely on load amelioration, but new ones are needed, according to investigators.

Health benefits last for at least 5 years if shedding pounds occur via a lifestyle change program, the results of a research review show.

Transplant patients must adhere to lifelong regimens and those caring for them must consider their regimen as the patients intersect with different parts of the health care system.

Pharmacists respond to questions about supplementation and and smoking cessation for heart health.

Key lifestyle risk factors for chronic diseases and cancers include tobacco use, poor nutrition, lack of physical movement, and obesity.

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.

At 1 year, patients receiving chemotherapy regimens containing anthracyclines for lymphoma who took statins had an average ejection fraction that was 1.3% higher than those who took placebo.

Rivaroxaban and aspirin results in a 33% reduction in major adverse limb events both early and late following lower extremity revascularization.

As evidence for omega-3 continues to develop, pharmacists remain poised to guide patients toward the most indicated, safe, effective, and convenient options available.

Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.

The proportion of patients prescribed high-intensity statin therapy increased by 3.8% across all clinics in the intervention arm.

Study participants without co-pays were slightly more likely to take their medications as prescribed for several medication classes.

Food insecurity was also higher among Hispanic and Black women compared with White women, with 1 in 4 Black women and 1 in 3 Hispanic women reporting food insecurity.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

In an interview with Pharmacy Times, Anastasia Armbruster, PharmD, FACC, BCCP, discussed her presentation at the American College of Cardiology 2023 Scientific Session.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.